Effects of gut hormones in individuals with altered receptor function
The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor Function
This study is testing how certain gut hormones affect people with specific genetic changes to see how they impact metabolism.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 1 site (Hellerup) |
| Trial ID | NCT06194955 on ClinicalTrials.gov |
What this trial studies
This project investigates the physiological effects of GIP, GLP-1, and GLP-2 hormone infusions in individuals carrying genetic variants affecting these receptors. Participants will undergo a series of randomized experimental days involving glucose tolerance tests and hormone infusions to assess their metabolic responses. The study aims to understand how these hormones function in individuals with specific genetic mutations, providing insights into their role in metabolism. Additionally, participants will undergo DXA scans and arginine tests to gather comprehensive data on their physiological status.
Who should consider this trial
Good fit: Ideal candidates are individuals with a BMI between 19-35 kg/m2 who carry mutations in the GIP, GLP-1, or GLP-2 receptors.
Not a fit: Patients with liver disease, decreased kidney function, or those on medications that cannot be paused may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for metabolic disorders related to incretin hormones.
How similar studies have performed: While the specific approach of this study is novel, similar studies investigating the effects of incretin hormones have shown promising results in understanding metabolic functions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI 19-35 kg/m2 Exclusion Criteria: * Treatment with medication or supplements that can not be discontinued for 12 hours * \>10 objects of alcohol weekly or abuse of narcotics * Liver disease (defined as ALAT and/or ASAT ≥ 2 x normal levels) * Decreased kidney function (creatine levels over reference interval) * Uncontrollable increased blood pressure (\> 140/90 mmHg) * Low blood percentage (hemoglobin \< 8.3 mmol/l) * Special diet or planned weight change during trial period * Other conditions that could be expected to affect the primary or secondary outcomes
Where this trial is running
Hellerup
- Center for Clinical Metabolic Research, Gentofte Hospital — Hellerup, Denmark (Recruiting)
Study contacts
- Study coordinator: Lærke S Gasbjerg, MD, PhD
- Email: lsg@sund.ku.dk
- Phone: +45 35322626
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.